Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Phase III nasal polyps data for Dupixent presented at AAAAI

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and partner Sanofi (Euronext:SAN; NYSE:SNY) presented detailed data at the American Academy of Allergy, Asthma & Immunology meeting from a pair of Phase III trials

Read the full 293 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE